U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Full FDA approval of Inluriyo plus Verzenio adds an all-oral option that doubled median progression-free survival in ESR1-mutated metastatic breast cancer.
Rhea-AI Summary
Eli Lilly (LLY) received full U.S. FDA approval for Inluriyo (imlunestrant) plus Verzenio (abemaciclib) to treat adults with ER+, HER2–, ESR1‑mutated locally advanced or metastatic breast cancer whose disease has progressed after at least one line of endocrine therapy, with ESR1 mutation detected by an FDA‑authorized test.
The approval is based on Phase 3 EMBER‑3, where Inluriyo+Verzenio after prior aromatase inhibitor±CDK4/6 inhibitor doubled median progression‑free survival versus Inluriyo alone (11.1 vs 5.5 months; HR=0.53; 95% CI 0.35–0.80) in 159 ESR1‑mutated patients. The all‑oral regimen targets estrogen receptor and CDK4/6 pathways and showed a safety profile consistent with the individual drugs, with most adverse events Grade 1–2 but 21% serious and 3.8% fatal reactions in the combination arm. The combination is now available in the United States.
Positive
- Median PFS doubled with Inluriyo+Verzenio vs Inluriyo alone (11.1 vs 5.5 months; HR=0.53) in ESR1-mutated MBC.
- Full FDA approval for adults with ER+, HER2–, ESR1‑mutated advanced or metastatic breast cancer after endocrine therapy.
- All-oral regimen targets both ER and CDK4/6 pathways with no new monitoring requirements beyond existing labels.
- Low discontinuation due to AEs in EMBER-3 combo arm: 1% for Inluriyo and 3.4% for Verzenio.
Negative
- Serious adverse reactions 21% and fatal reactions 3.8% with Inluriyo+Verzenio in EMBER-3.
- High diarrhea incidence: 86% any grade and 9% Grade 3–4 with the combination.
- Neutrophil decreases in 86% of combo patients; 21% Grade 3–4, requiring blood count monitoring.
- Venous thromboembolism 4.8% and ILD/pneumonitis 2.9% with the combination necessitate close clinical surveillance.
News Explained
Although Lilly says the combination requires no new monitoring, its safety information directs complete blood counts and liver-function tests before treatment and at defined intervals for Verzenio, so the approval includes ongoing laboratory monitoring.
Key Figures
- Trial population
- 159 patients
- Phase 3 EMBER-3 ESR1-mutated MBC population
- Median PFS
- 11.1 months vs. 5.5 months
- Inluriyo plus Verzenio versus Inluriyo alone
- Hazard ratio
- 0.53 [95% CI, 0.35–0.80]
- Progression-free survival in EMBER-3
- Diarrhea
- 86%
- Patients receiving Inluriyo plus Verzenio
- Grade 3 or 4 diarrhea
- 9%
- Patients receiving Inluriyo plus Verzenio
- Serious adverse reactions
- 21%
- Patients receiving Inluriyo plus Verzenio
- Fatal adverse reactions
- 3.8%
- Patients receiving Inluriyo plus Verzenio
Previous Fda approval Reports
-
Prior monotherapy approval for ESR1-mutated metastatic breast cancer after endocrine therapy.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
esr1 mutation medical
cdk4/6 inhibitor medical
progression-free survival medical
oral serd medical
embryo-fetal toxicity medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Inluriyo plus Verzenio delivers proven clinical benefit after the evidence-based practice of maximizing initial treatment with an aromatase inhibitor, with or without a CDK4/6 inhibitor
In the Phase 3 EMBER-3 trial, Inluriyo in combination with Verzenio doubled median progression-free survival compared to Inluriyo alone, among patients with ESR1-mutated MBC
The all-oral combination of Inluriyo and Verzenio gives patients a treatment approach that targets the two central drivers of ER+ breast cancer, with an established tolerability profile and no new monitoring required
"In less than a year since its approval, Inluriyo is the leading treatment option for people with ER+, HER2–, ESR1m metastatic breast cancer, now reaching over half of all patients starting an oral SERD," said Jacob Van Naarden, executive vice president and president of Lilly Oncology. "Today's full approval extends what Inluriyo in combination with Verzenio can do for patients, with a regimen that has confirmed benefit, is aligned to the clinically proven treatment paradigm of changing therapy at clinical progression, and doesn't introduce burdensome monitoring requirements for patients or physicians. In fact, all available evidence suggests that switching endocrine therapy and CDK4/6 inhibitor at clinical progression improves patient outcomes more than switching therapy earlier. Utilizing this evidence-based practice spares early exposure to additional side effects, reduces patient anxiety from unnecessary testing, and mitigates avoidable costs to the healthcare system."
This full FDA approval is based on the results of the Phase 3 EMBER-3 trial in patients with MBC whose tumors harbor an ESR1 mutation (n=159). Patients received Inluriyo (n=92) or Inluriyo in combination with Verzenio (n=67) after an aromatase inhibitor (AI), with or without a CDK4/6 inhibitor, in either the adjuvant or metastatic setting. Among patients with ESR1-mutated MBC, Inluriyo in combination with Verzenio doubled median progression-free survival (PFS) versus Inluriyo alone, with a median PFS of 11.1 months versus 5.5 months (HR=0.53 [
"We have an urgent need for effective and safe treatment options for patients with disease progression on adjuvant or first-line therapy. Combining therapies that work on two distinct drivers of tumor growth—the estrogen receptor and CDK4/6—is an important strategy to help address treatment resistance," said Komal Jhaveri, MD, FACP, FASCO, Associate Attending Breast Medicine and Early Drug Development Services, section head of the Endocrine Therapy Research Program at Memorial Sloan Kettering Cancer Center, and principal investigator for the EMBER-3 and EMBER-4 trials. "In EMBER-3, switching both the endocrine therapy and CDK 4/6 inhibitor, for the majority of patients, to imlunestrant plus abemaciclib at disease progression achieved a median progression-free survival of 11.1 months and a safety profile consistent with that of each medicine individually, establishing a meaningful new treatment option."
In about half of patients with ER+, HER2– MBC, tumors develop a genetic change called an ESR1 mutation during or after treatment with a common class of hormone-blocking medicines known as AIs. These mutations can cause estrogen receptors to become overactive, fueling cancer growth. Inluriyo and Verzenio target two different drivers of tumor growth, offering a combined approach to help slow the disease. Inluriyo degrades mutated estrogen receptors, cutting off the signal that drives cancer cells to grow. Verzenio targets proteins that control how quickly cancer cells divide, helping to slow their growth.
The Inluriyo label contains a warning and precaution for embryo-fetal toxicity. See Important Safety Information below and full Prescribing Information for additional information.
The Verzenio label contains warnings and precautions for severe diarrhea, neutropenia, interstitial lung disease/pneumonitis, hepatotoxicity, venous thromboembolism, embryo-fetal toxicity, and increased serum creatinine without affecting renal function. See Important Safety Information below and full Prescribing Information for additional information.
In EMBER-3, the majority of adverse events (AEs) with Inluriyo in combination with Verzenio were Grade 1-2. The most common (≥
This marks the second FDA approval for Inluriyo in less than a year, following its September 2025 approval as monotherapy for the treatment of adults with ER+, HER2–, ESR1-mutated MBC whose disease progressed after at least one line of endocrine therapy (ET).
Inluriyo is also being studied in the Phase 3 EMBER-4 trial (NCT05514054) in the adjuvant setting for people with ER+, HER2– early-stage breast cancer (EBC) at increased risk of recurrence following standard of care endocrine therapy, including CDK4/6 inhibitors. EMBER-4 is the largest adjuvant oral SERD clinical trial, with more than 8,000 patients enrolled worldwide across 650+ sites in 30+ countries. Initial results are anticipated in 2027.
Inluriyo in combination with Verzenio is now available in
See Important Safety Information below and full Prescribing Information for additional information.
About Inluriyo (imlunestrant)
Inluriyo (imlunestrant) (pronounced en-loo-ree-yoh) is an oral estrogen receptor antagonist that delivers continuous ER inhibition, including in ESR1-mutant cancers. The estrogen receptor (ER) is the key therapeutic target for patients with ER+, HER2– breast cancer. Inluriyo is a U.S. FDA approved oral prescription medicine, 200 mg tablets taken as a once-daily dose of 400 mg taken on an empty stomach, at least 2 hours before food or 1 hour after food. Inluriyo is also currently being studied as an adjuvant treatment in early breast cancer in the Phase 3 EMBER-4 trial (NCT05514054).
For full details on indicated uses of Inluriyo in ER+, HER2– ESR1m metastatic breast cancer, please see full Prescribing Information, available at www.inluriyo.lilly.com.
About Verzenio® (abemaciclib)
Verzenio (abemaciclib) is approved to treat people with certain HR+, HER2– breast cancers in the adjuvant and advanced or metastatic settings.
Verzenio is an oral tablet taken twice daily and available in strengths of 50 mg, 100 mg, 150 mg, and 200 mg. Discovered and developed by Lilly researchers, Verzenio was first approved in 2017 and is authorized for use in more than 90 countries around the world.
For full details on indicated uses of Verzenio in HR+, HER2– breast cancer, please see full Prescribing Information, available at www.verzenio.lilly.com.
Important Safety Information for Inluriyo® (imlunestrant) as Monotherapy and in Combination with Verzenio® (abemaciclib)
Diarrhea: Severe diarrhea associated with dehydration and infection occurred in patients treated with Verzenio. Instruct patients at the first sign of loose stools to initiate antidiarrheal therapy, increase oral fluids, and notify their healthcare provider. In EMBER-3, diarrhea occurred in
Neutropenia: Neutropenia, including febrile neutropenia and fatal neutropenic sepsis, occurred in patients treated with Verzenio. In EMBER-3, neutrophil count decreased in
Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis can occur in patients treated with Verzenio and other CDK4/6 inhibitors. In EMBER-3, ILD or pneumonitis occurred in
Hepatotoxicity: Increases in serum transaminase levels have been observed. Perform liver function tests (LFTs) before initiating treatment with Verzenio. Monitor LFTs every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated with Verzenio. Monitor ALT and AST during treatment with Inluriyo as clinically indicated. In EMBER-3, ALT increase occurred in
Venous Thromboembolism: Deaths due to venous thromboembolism have been reported in patients treated with Verzenio. In EMBER-3, venous thromboembolic events occurred in
Embryo-Fetal Toxicity: Inluriyo and Verzenio can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Verify pregnancy status in females of reproductive potential prior to initiating treatment. Advise females of reproductive potential to use effective contraception during treatment with Inluriyo in combination with Verzenio and for 3 weeks after the last dose of Verzenio or 1 week after the last dose of Inluriyo, whichever is longer. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 1 week after the last dose of Inluriyo.
For Inluriyo monotherapy, advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with Inluriyo and for 1 week after the last dose.
Increased Serum Creatinine Without Affecting Renal Function: Verzenio can increase serum creatinine. These increases were not associated with changes in glomerular function. In EMBER-3, creatinine increase occurred in
Serious and Fatal Adverse Reactions for Inluriyo in combination with Verzenio: Serious adverse reactions occurred in
Most Common Adverse Reactions for Inluriyo in combination with Verzenio: The most common (≥
Serious and Fatal Adverse Reactions for Inluriyo Monotherapy: Serious adverse reactions occurred in
Most Common Adverse Reactions for Inluriyo Monotherapy: The most common (≥
Drug Interactions – Inluriyo:
- Avoid concomitant use with strong CYP3A inhibitors. If concomitant use cannot be avoided, decrease the Inluriyo dosage. Avoid concomitant use with strong CYP3A inducers. If concomitant use cannot be avoided, increase the Inluriyo dosage. See Prescribing Information for recommended dosage modifications.
- Imlunestrant inhibits both P-gp and BCRP. Avoid concomitant use unless otherwise recommended in the Prescribing Information for P-gp or BCRP substrates where minimal concentration changes may lead to serious adverse reactions.
Drug Interactions – Verzenio:
- CYP3A Inhibitors: Avoid concomitant use of ketoconazole. Reduce the Verzenio dose with concomitant use of other strong and moderate CYP3A inhibitors. Monitor for adverse reactions and follow the specific dose modification instructions located in the Prescribing Information. Patients should avoid grapefruit products.
- CYP3A Inducers: Avoid concomitant use of strong and moderate CYP3A inducers and consider alternative agents.
Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise lactating women to not breastfeed during treatment with Inluriyo in combination with Verzenio and for 3 weeks after the last dose of Verzenio or 1 week after the last dose of Inluriyo, whichever is longer.
For Inluriyo monotherapy, advise lactating women to not breastfeed during treatment with Inluriyo and for 1 week after the last dose.
Hepatic Impairment: With Inluriyo, reduce the dose in patients with moderate or severe hepatic impairment. The recommended dosage for patients with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment is 200 mg once daily. No dosage modification is recommended for patients with mild hepatic impairment (Child-Pugh A).
With Verzenio, reduce the dosing frequency to once daily in patients with severe hepatic impairment (Child-Pugh C). No dosage adjustments are necessary in patients with mild or moderate hepatic impairment (Child-Pugh A or B).
Inluriyo may impair fertility in females and males of reproductive potential.
Verzenio may impair fertility in males of reproductive potential.
Inluriyo (imlunestrant) is available as 200 mg tablets.
Verzenio (abemaciclib) is available as 50 mg, 100 mg, 150 mg, and 200 mg tablets.
Please click to access full Prescribing Information for Inluriyo and Verzenio.
IN VZ HCP ISI Combo+Mono APPR
Frequently Asked Questions
1. What is Inluriyo (imlunestrant)?
Inluriyo (imlunestrant) is an FDA-approved oral estrogen receptor antagonist also described as an oral selective estrogen receptor degrader, or oral SERD. It is designed to bind to the estrogen receptor (ER) and inhibit ER-driven signaling. In September 2025, Inluriyo (imlunestrant) was FDA-approved for treatment of adults with ER+, HER2–, ESR1-mutated advanced or metastatic breast cancer (MBC) with disease progression following at least one line of endocrine therapy. In September 2026, Inluriyo in combination with Verzenio was approved for the treatment of adults with ER+, HER2–, ESR1-mutated advanced or MBC, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
2. What is Verzenio (abemaciclib)?
Verzenio (abemaciclib) is approved to treat people with certain HR+, HER2– breast cancers in the adjuvant and advanced or metastatic setting. Verzenio is the first CDK4/6 inhibitor approved to treat node-positive, high risk early breast cancer (EBC) patients. In high risk EBC, Verzenio has shown a persistent and deepening benefit beyond the two-year treatment period in the monarchE trial, an adjuvant study designed specifically to investigate a CDK4/6 inhibitor in a node-positive, high risk EBC population. In metastatic breast cancer, Verzenio has demonstrated statistically significant overall survival in the Phase 3 MONARCH 2 study. Verzenio has shown a consistent and generally manageable safety profile across clinical trials.
3. What are the clinical benefits of the Inluriyo (imlunestrant) and Verzenio (abemaciclib) combination?
In an analysis of the primary outcome data, Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) doubled progression-free survival [11.1 months versus 5.5 months with Inluriyo (imlunestrant) alone (HR=0.53 [
4. What type of FDA approval did Inluriyo in combination with Verzenio receive?
Inluriyo in combination with Verzenio received full approval from the FDA for the treatment of adults with ER+, HER2–, ESR1-mutated advanced or MBC based on the results of the Phase 3 EMBER-3 trial. Full approval is not contingent on confirmatory trial results, distinguishing it from accelerated approval, which the FDA grants based on a surrogate endpoint likely to predict clinical benefit and requires confirmatory trials to verify that benefit.
5. Do Inluriyo (imlunestrant) or Verzenio (abemaciclib) have any black box warnings?
Neither Inluriyo or Verzenio have boxed warnings.
6. What is metastatic or locally advanced breast cancer?
Metastatic or advanced breast cancer (MBC) is defined as breast cancer that has spread from the breast to other parts of the body. Locally advanced breast cancer has grown beyond the breast to nearby tissue or lymph nodes, but has not spread to other parts of the body.1 Of all high risk early-stage breast cancer cases diagnosed in the
7. Why are estrogen receptors important in treating breast cancer?
Approximately
8. How does Inluriyo (imlunestrant) target the estrogen receptor?
Inluriyo (imlunestrant) is an estrogen receptor (ER) antagonist that works by binding to ER, switching off signals that tell cancer cells to grow, and triggering ER to be broken down, thus slowing cancer growth. Within the oncology community, this approach is often referred to as a selective estrogen receptor degrader (SERD).
9. Why are oral SERDs important for patients with treatment-resistant ER+ breast cancer?
Up to
10. In which Phase 3 clinical trials is Inluriyo (imlunestrant) being studied?
Inluriyo is currently being studied in two clinical trials:
- EMBER-3 (NCT04975308) is a Phase 3, randomized, open-label study of Inluriyo (imlunestrant), investigator's choice of endocrine therapy, and Inluriyo in combination with abemaciclib in patients with ER+, HER2– locally advanced or metastatic breast cancer (MBC), as detected by an FDA-authorized test, whose disease has recurred or progressed during or following an aromatase inhibitor (AI) therapy with or without a CDK 4/6 inhibitor. More information on the EMBER-3 study can be found on clinicaltrials.gov.
- EMBER-4 (NCT05514054) is a Phase 3, randomized, open-label study of adjuvant Inluriyo (imlunestrant) versus standard adjuvant endocrine therapy in patients with ER+, HER2– early breast cancer with an increased risk of recurrence following initial endocrine therapy, with or without a CDK4/6 inhibitor. More information on the EMBER-4 study can be found on clinicaltrials.gov.
11. What makes EMBER-4 different from other adjuvant breast cancer trials?
The Phase 3 EMBER-4 trial is the largest oral SERD study, enrolling more than 8,000 patients across 650+ sites in 30+ countries. The trial is studying Inluriyo (imlunestrant) in patients with ER+, HER2– early breast cancer at increased risk of recurrence, in the adjuvant (post-surgery) setting.
EMBER-4 was designed as a sequential trial: patients were enrolled following initial standard adjuvant endocrine therapy, including patients with or without prior CDK4/6 inhibitor treatment. This design mirrors how patients are actually treated today. It asks the question: can Inluriyo (imlunestrant) provide additional protection for patients who have already received initial standard of care hormone therapy with or without a CDK4/6 inhibitor, when risk of recurrence increases.
About Breast Cancer
Breast cancer is the second most commonly diagnosed cancer worldwide (following lung cancer), according to GLOBOCAN. The estimated 2.3 million new cases indicate that close to 1 in every 4 cancers diagnosed in 2022 is breast cancer. With approximately 666,000 deaths in 2022, breast cancer is the fourth-leading cause of cancer death worldwide.5 In the U.S., it is estimated that there will be more than 310,000 new cases of breast cancer diagnosed in 2024. Breast cancer is the second leading cause of cancer death in women in the U.S.6
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY
CMAT-44358 09/2026
© Lilly USA, LLC 2026. ALL RIGHTS RESERVED.
MSK Disclosure: Dr. Jhaveri has financial interests related to Eli Lilly and Company.
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Inluriyo in combination with Verzenio as a treatment for people with certain types of breast cancer and other conditions and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that Inluriyo plus Verzenio will receive additional regulatory approvals, or that Inluriyo plus Verzenio will be commercially successful. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Endnotes & References
- André F, et al. Ann Oncol. 2021;32(2): 208-217.
- O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10 Suppl 3:20-9. PMID: 16368868 DOI: 10.1634/theoncologist.10-90003-20
- Metastatic Breast Cancer Network. 13 Facts about Metastatic Breast Cancer. http://www.mbcn.org/13-facts-about-metastatic-breast-cancer/. Accessed September 2026.
- American Cancer Society. Breast Cancer Facts & Figures 2022-2024. Atlanta: American Cancer Society, Inc. 2022. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2022-2024-breast-cancer-fact-figures-acs.pdf. Accessed September 2026.
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
- American Cancer Society. Cancer Statistics Center. http://cancerstatisticscenter.cancer.org. Accessed September 2026.
|
Refer to: |
Michelle Webb; michelle.webb@lilly.com; 463-206-4463 (Media) |
|
|
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/us-fda-approves-inluriyo-imlunestrant-in-combination-with-verzenio-abemaciclib-for-adults-with-er-her2-esr1-mutated-advanced-or-metastatic-breast-cancer-302883515.html
SOURCE Eli Lilly and Company
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What specific patient population is eligible for Inluriyo plus Verzenio under this approval?
The combination is approved for adults with estrogen receptor‑positive (ER+), HER2‑negative, ESR1‑mutated locally advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy. The ESR1 mutation must be detected by an FDA‑authorized test.
How was Inluriyo plus Verzenio used in the EMBER-3 trial to support approval?
In EMBER‑3, patients with ESR1‑mutated metastatic breast cancer previously treated with an aromatase inhibitor, with or without a CDK4/6 inhibitor in the adjuvant or metastatic setting, were randomized to Inluriyo alone (n=92) or Inluriyo+Verzenio (n=67). The efficacy results from this post‑AI setting formed the basis of approval.
What are the most common side effects seen with Inluriyo in combination with Verzenio?
The most common (≥10%) adverse reactions, including lab abnormalities, with the combination were decreased neutrophils, diarrhea, decreased hemoglobin, decreased lymphocytes, nausea, decreased platelets, fatigue, increased triglycerides, infections, increased AST, increased creatinine, increased ALT, vomiting, musculoskeletal pain, abdominal pain, decreased appetite, increased cholesterol, rash, cough, headache, and decreased weight.
Are there important safety warnings for Inluriyo and Verzenio that clinicians must consider?
Key warnings for the combination include diarrhea, neutropenia, interstitial lung disease/pneumonitis, hepatotoxicity, venous thromboembolism, embryo‑fetal toxicity, and increased serum creatinine without affecting renal function. The Inluriyo label also carries an embryo‑fetal toxicity warning, and both agents have detailed dose‑modification and monitoring guidance in their Prescribing Information.
What are the dosing characteristics of Inluriyo as described in the announcement?
Inluriyo is an oral estrogen receptor antagonist supplied as 200 mg tablets, taken as a once‑daily 400 mg dose on an empty stomach, at least 2 hours before food or 1 hour after food.
Is Inluriyo being studied in earlier-stage breast cancer settings?
Yes. Inluriyo is being evaluated in the Phase 3 EMBER‑4 trial (NCT05514054) as adjuvant treatment for people with ER+, HER2– early-stage breast cancer at increased risk of recurrence after standard endocrine therapy, including CDK4/6 inhibitors. EMBER‑4 has enrolled more than 8,000 patients across 650+ sites in over 30 countries, with initial results anticipated in 2027.